{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:21:34Z","timestamp":1790738494747,"version":"4.1.0"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T00:00:00Z","timestamp":1672790400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Cardiovascular disease has become the primary disease that threatens human health and is considered the leading cause of death. Cardiac remodeling, which is associated with cardiovascular disease, mainly manifests as cardiac hypertrophy, fibrosis, inflammation, and oxidative stress. Farrerol plays an important role in treating conditions such as inflammation, endothelial injury and tumors, and we speculated that Farrerol may also play an important role in mitigating cardiac hypertrophy and remodeling. We established a model of myocardial remodeling using Angiotensin II (Ang II) with concurrent intraperitoneal injection of Farrerol as an intervention. We used cardiac ultrasound, immunohistochemistry, Immunofluorescence, Wheat Germ Agglutinin, Dihydroethidium, Western Blot, qPCR and other methods to detect the role of Farrerol in cardiac remodeling. The results showed that Farrerol inhibited Ang II-induced cardiac hypertrophy; decreased the ratio of heart weight to tibia length in mice; reduced inflammation, fibrosis, and oxidative stress; and reduced the size of cardiomyocytes <jats:italic>in vivo<\/jats:italic>. Farrerol inhibited Ang II-induced cardiomyocyte hypertrophy, levels of oxidative stress, and the proliferation and migration of fibroblast <jats:italic>in vitro<\/jats:italic>. Our results revealed that Farrerol could inhibit Ang II-induced cardiac remodeling. Farrerol may therefore be a candidate drug for the treatment of myocardial remodeling.<\/jats:p>","DOI":"10.3389\/fphar.2022.1079251","type":"journal-article","created":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T15:21:08Z","timestamp":1672845668000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Farrerol prevents Angiotensin II-induced cardiac remodeling in vivo and in vitro"],"prefix":"10.3389","volume":"13","author":[{"given":"Jian","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dengyue","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,1,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.jchf.2019.06.004","article-title":"Imaging, biomarker, and clinical predictors of cardiac remodeling in heart failure with reduced ejection fraction","volume":"7","author":"Aimo","year":"2019","journal-title":"JACC-Heart Fail"},{"key":"B2","doi-asserted-by":"publisher","first-page":"3336","DOI":"10.3390\/cells11213336","article-title":"Angiotensin ii-induced signal transduction mechanisms for cardiac hypertrophy","volume":"11","author":"Bhullar","year":"2022","journal-title":"Cells"},{"key":"B3","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13293-021-00396-x","article-title":"Angiotensin ii type 1 receptor agonistic autoantibody blockade improves postpartum hypertension and cardiac mitochondrial function in rat model of preeclampsia","volume":"12","author":"Booz","year":"2021","journal-title":"Biol. Sex. Differ."},{"key":"B4","doi-asserted-by":"publisher","first-page":"9400","DOI":"10.3390\/ijms22179400","article-title":"Farrerol induces cancer cell death via erk activation in skov3 cells and attenuates tnf-alpha-mediated lipolysis","volume":"22","author":"Chae","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B5","doi-asserted-by":"publisher","first-page":"5430407","DOI":"10.1155\/2020\/5430407","article-title":"Natural drugs as a treatment strategy for cardiovascular disease through the regulation of oxidative stress","volume":"2020","author":"Chang","year":"2020","journal-title":"Oxidative Med. Cell. Longev."},{"key":"B6","doi-asserted-by":"publisher","first-page":"108921","DOI":"10.1016\/j.cbi.2019.108921","article-title":"Farrerol alleviates high glucose-induced renal mesangial cell injury through the ros\/nox4\/erk1\/2 pathway","volume":"316","author":"Chen","year":"2020","journal-title":"Chem.-Biol. Interact."},{"key":"B7","doi-asserted-by":"publisher","first-page":"7709","DOI":"10.3390\/ijms23147709","article-title":"Of mouse and man: Cross-species characterization of hypertensive cardiac remodeling","volume":"23","author":"Cooper","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B8","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.biopha.2018.10.053","article-title":"Farrerol attenuates beta-amyloid-induced oxidative stress and inflammation through nrf2\/keap1 pathway in a microglia cell line","volume":"109","author":"Cui","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"B9","doi-asserted-by":"publisher","first-page":"154238","DOI":"10.1016\/j.phymed.2022.154238","article-title":"Tabersonine attenuates angiotensin ii-induced cardiac remodeling and dysfunction through targeting tak1 and inhibiting tak1-mediated cardiac inflammation","volume":"103","author":"Dai","year":"2022","journal-title":"Phytomedicine"},{"key":"B10","doi-asserted-by":"publisher","first-page":"566410","DOI":"10.3389\/fphys.2020.566410","article-title":"Angiotensin ii decreases endothelial nitric oxide synthase phosphorylation via at1r nox\/ros\/pp2a pathway","volume":"11","author":"Ding","year":"2020","journal-title":"Front. Physiol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1146\/annurev-physiol-012110-142230","article-title":"Myocardial remodeling: Cellular and extracellular events and targets","volume":"73","author":"Dixon","year":"2011","journal-title":"Annu. Rev. Physiol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12986-017-0200-8","article-title":"Hyperglycemia-induced oxidative stress and heart disease-cardioprotective effects of rooibos flavonoids and phenylpyruvic acid-2-o-beta-d-glucoside","volume":"14","author":"Dludla","year":"2017","journal-title":"Nutr. Metab."},{"key":"B13","doi-asserted-by":"publisher","first-page":"105599","DOI":"10.1016\/j.phrs.2021.105599","article-title":"Suppression of apoptosis in vascular endothelial cell, the promising way for natural medicines to treat atherosclerosis","volume":"168","author":"Duan","year":"2021","journal-title":"Pharmacol. Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.yjmcc.2022.07.012","article-title":"PGE2 protects against heart failure through inhibiting TGF-\u03b21 synthesis in cardiomyocytes and crosstalk between TGF-\u03b21 and GRK2","volume":"172","author":"Fu","year":"2022","journal-title":"J. Mol. Cell. Cardiol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e23157","DOI":"10.1002\/jbt.23157","article-title":"Farrerol exhibits inhibitory effects on lung adenocarcinoma cells by activating the mitochondrial apoptotic pathway","volume":"36","author":"Guo","year":"2022","journal-title":"J. Biochem. Mol. Toxicol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"105962","DOI":"10.1016\/j.intimp.2019.105962","article-title":"Corrigendum to 'Farrerol protects dopaminergic neurons in a rat model of lipopolysaccharide-induced Parkinson's disease by suppressing the activation of the AKT and NF-\u03baB signaling pathways'. [Int. Immunopharmacol. 75 (2019) 105739]","volume":"75","author":"Li","year":"2019","journal-title":"Int. Immunopharmacol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1124\/pharmrev.120.000236","article-title":"Kidney angiotensin in cardiovascular disease: Formation and drug targeting","volume":"74","author":"Lin","year":"2022","journal-title":"Pharmacol. Rev."},{"key":"B18","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1093\/ajh\/hpw104","article-title":"Hydrogen sulfide improves myocardial remodeling via downregulated angiotensin\/at1r pathway in renovascular hypertensive rats","volume":"30","author":"Liu","year":"2017","journal-title":"Am. J. Hypertens."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.3389\/fphys.2019.01419","article-title":"Farrerol attenuates cisplatin-induced nephrotoxicity by inhibiting the reactive oxygen species-mediated oxidation, inflammation, and apoptotic signaling pathways","volume":"10","author":"Ma","year":"2019","journal-title":"Front. Physiol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"768700","DOI":"10.3389\/fphar.2021.768700","article-title":"Farrerol ameliorated cisplatin-induced chronic kidney disease through mitophagy induction via nrf2\/pink1 pathway","volume":"12","author":"Ma","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1161\/CIRCRESAHA.108.182899","article-title":"Statins use a novel nijmegen breakage syndrome-1-dependent pathway to accelerate dna repair in vascular smooth muscle cells","volume":"103","author":"Mahmoudi","year":"2008","journal-title":"Circ. Res."},{"key":"B22","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1536\/ihj.20-034","article-title":"Reverse remodeling and current medical therapy in heart failure with reduced ejection fraction","volume":"61","author":"Maki","year":"2020","journal-title":"Int. Heart J."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1111\/jcmm.17215","article-title":"Regulation of total lc3 levels by angiotensin ii in vascular smooth muscle cells","volume":"26","author":"Mondaca-Ruff","year":"2022","journal-title":"J. Cell. Mol. Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"eaay2176","DOI":"10.1126\/scitranslmed.aay2176","article-title":"Inhibition of aquaporin-1 prevents myocardial remodeling by blocking the transmembrane transport of hydrogen peroxide","volume":"12","author":"Montiel","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/jhh.2014.36","article-title":"Myocardial remodeling in hypertension","volume":"29","author":"Nadruz","year":"2015","journal-title":"J. Hum. Hypertens."},{"key":"B26","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1023\/B:HREV.0000011391.81676.3c","article-title":"Myocardial remodeling in viral heart disease: Possible interactions between inflammatory mediators and mmp-timp system","volume":"9","author":"Pauschinger","year":"2004","journal-title":"Heart fail. Rev."},{"key":"B27","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.pharmthera.2009.05.002","article-title":"Cardiac fibroblasts: At the heart of myocardial remodeling","volume":"123","author":"Porter","year":"2009","journal-title":"Pharmacol. Ther."},{"key":"B28","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1080\/13880209.2021.2006723","article-title":"The pharmacological properties and corresponding mechanisms of farrerol: A comprehensive review","volume":"60","author":"Qin","year":"2022","journal-title":"Pharm. Biol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"101650","DOI":"10.1016\/j.redox.2020.101650","article-title":"Nicotinamide nucleotide transhydrogenase (nnt) regulates mitochondrial ros and endothelial dysfunction in response to angiotensin ii","volume":"36","author":"Rao","year":"2020","journal-title":"Redox Biol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1161\/CIRCRESAHA.118.313280","article-title":"Strength in numbers: Cardiac fibroblast clustering and myocardial remodeling","volume":"123","author":"Turner","year":"2018","journal-title":"Circ. Res."},{"key":"B31","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1007\/s11906-012-0305-4","article-title":"Mitochondria, myocardial remodeling, and cardiovascular disease","volume":"14","author":"Verdejo","year":"2012","journal-title":"Curr. Hypertens. Rep."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1161\/CIRCULATIONAHA.115.020754","article-title":"Genetic and pharmacologic inhibition of the chemokine receptor cxcr2 prevents experimental hypertension and vascular dysfunction","volume":"134","author":"Wang","year":"2016","journal-title":"Circulation"},{"key":"B33","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1007\/s00018-017-2452-x","article-title":"The role of neuropeptides in adverse myocardial remodeling and heart failure","volume":"74","author":"Widiapradja","year":"2017","journal-title":"Cell. Mol. Life Sci."},{"key":"B34","doi-asserted-by":"publisher","first-page":"3483","DOI":"10.1111\/jcmm.17388","article-title":"Farrerol alleviates collagenase-induced tendinopathy by inhibiting ferroptosis in rats","volume":"26","author":"Wu","year":"2022","journal-title":"J. Cell. Mol. Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"5967434","DOI":"10.1155\/2020\/5967434","article-title":"Farrerol directly targets GSK-3\u03b2 to activate nrf2-ARE pathway and protect EA.hy926 cells against oxidative stress-induced injuries","volume":"2020","author":"Yan","year":"2020","journal-title":"Oxidative Med. Cell. Longev."},{"key":"B36","doi-asserted-by":"publisher","first-page":"3470","DOI":"10.3390\/molecules24193470","article-title":"A complete study of farrerol metabolites produced in vivo and in vitro","volume":"24","author":"Yin","year":"2019","journal-title":"Molecules"},{"key":"B37","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s11897-007-0022-5","article-title":"Role of reactive oxygen species in myocardial remodeling","volume":"4","author":"Zhang","year":"2007","journal-title":"Curr. Heart Fail. Rep."},{"key":"B38","doi-asserted-by":"publisher","first-page":"700","DOI":"10.2174\/1381612825666190408122557","article-title":"Hyperuricemia and cardiovascular disease","volume":"25","author":"Zhang","year":"2019","journal-title":"Curr. Pharm. Des."},{"key":"B39","doi-asserted-by":"publisher","first-page":"174636","DOI":"10.1016\/j.ejphar.2021.174636","article-title":"Farrerol suppresses the progression of laryngeal squamous cell carcinoma via the mitochondria-mediated pathway","volume":"913","author":"Zhang","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1161\/HYPERTENSIONAHA.117.10156","article-title":"Apelin is a negative regulator of angiotensin ii-mediated adverse myocardial remodeling and dysfunction","volume":"70","author":"Zhang","year":"2017","journal-title":"Hypertension"},{"key":"B41","doi-asserted-by":"publisher","first-page":"107698","DOI":"10.1016\/j.pharmthera.2020.107698","article-title":"Current state and future perspective of cardiovascular medicines derived from natural products","volume":"216","author":"Zhao","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"B42","doi-asserted-by":"publisher","first-page":"879232","DOI":"10.3389\/fphar.2022.879232","article-title":"Farrerol alleviates myocardial ischemia\/reperfusion injury by targeting macrophages and nlrp3","volume":"13","author":"Zhou","year":"2022","journal-title":"Front. Pharmacol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.1079251\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T15:21:11Z","timestamp":1672845671000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.1079251\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,4]]},"references-count":42,"alternative-id":["10.3389\/fphar.2022.1079251"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.1079251","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,4]]},"article-number":"1079251"}}